BLUE BELL, Pa., Sept. 18, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that Dr. J. Joseph Kim, President and CEO, will be presenting an overview of the company at the Aegis Capital Corp. Healthcare Conference and BioCentury's 20th Annual NewsMakers in the Biotech Industry Conference. He will also be the invited speaker at the Town Hall Los Angeles meeting on Tuesday, September 24, 2013. In his speech titled, "Are We Prepared for the Next Pandemic Flu Virus? Is a New Universal Vaccine the Answer," Dr. Kim will discuss the potential devastating effects of an influenza pandemic and how medicine is working urgently to meet the next pandemic.
Aegis Capital Corp. Healthcare Conference
September 25-28, 2013
The Encore at Wynn Las Vegas
Las Vegas, NV
Thursday, September 26, 2013
8:30 AM PT
BioCentury's 20th Annual NewsMakers in the Biotech Industry Conference
September 27, 2013
Millennium Broadway Hotel
New York, NY
Friday, September 27, 2013
11:30 AM ET
A live and archived webcast of the NewsMakers presentation will be accessible on the homepage of Inovio's website under the webcast tab at www.inovio.com.
Town Hall Los Angeles
September 24, 2013
11:30 AM -1:30 PM PT
Millennium Biltmore Hotel
Los Angeles, CA
Individuals interested in attending may register online.
About Town Hall Los Angeles
Town Hall Los Angeles is recognized as one of the Top 10 Executive Leadership Forums. They invite one compelling and newsworthy speaker to their luncheon forum each month to present issues that affect Angelenos and provide a platform for the discussion of solutions from a nonpartisan point of view. The audience of the forum draws from the top business leaders across industries in the area.
About Inovio Pharmaceuticals, Inc.
Inovio is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon® vaccines, in combination with its proprietary electroporation delivery, are generating best-in-class immune responses, with therapeutic T-cell responses exceeding other technologies in terms of magnitude, breadth, and response rate. Human data to date have shown a favorable safety profile. Inovio's lead vaccine, a therapeutic against HPV-caused pre-cancers and cancers, is in phase II. Other phase I and preclinical programs target prostate, breast, and lung cancers as well as HIV, influenza, malaria and hepatitis C virus. Partners and collaborators include the University of Pennsylvania, Merck, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, University of Southampton, US Dept. of Homeland Security, University of Manitoba and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.
This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2012, our Form 10-Q for the quarter ended June 30, 2013, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.
Investors: Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101, email@example.com
Media: Jeff Richardson, Inovio Pharmaceuticals, 267-440-4211, firstname.lastname@example.org
SOURCE Inovio Pharmaceuticals, Inc.